<DOC>
	<DOCNO>NCT01739660</DOCNO>
	<brief_summary>This Phase 1 single dose study conduct evaluate PK PD pegloticase administer hemodialysis patient . A single dose pegloticase administer intravenously male female hemodialysis patient ( N = 12 ) start 3 hour prior dialysis . The study consist Screening Period , Treatment Period , Follow Period .</brief_summary>
	<brief_title>Study Assess Pegloticase ( KRYSTEXXA® ) Patients Hemodialysis</brief_title>
	<detailed_description>End stage renal disease ( ESRD ) patient require hemodialysis typically undergo hemodialysis treatment 3 time per week . As , medication dialyze , reduce clinical effectiveness ; study conduct understand dialysis affect pharmacokinetics ( PK ) pharmacodynamics ( PD ) pegloticase .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . 18 75 year age , inclusive 2 . Agrees employ best possible method abstain become pregnant impregnate another . 3 . Stage V chronic kidney patient minimal residual renal function receive hemodialysis stable hemodialysis ( 3x week ) 4 . BMI = 18.5 kg/m2 &lt; 45 kg/m2 1 . Any surgical medical condition may interfere drug absorption , distribution , metabolism , excretion , condition may place subject risk 1 . Glucose6phosphate dehydrogenase ( G6PD ) deficiency 2 . Uncontrolled congestive heart failure 3 . Refractory chronic gout 2 . History drug and/or alcohol abuse within 6 month prior screen 3 . History current clinically significant mental disorder antagonistic personality compromise validity inform consent 4 . Donation blood plasma within 30 day prior dose 5 . History current hepatitis , carrier hepatitis B surface antigen ( HbsAg ) and/or hepatitis C antibody ( antiHC ) . 6 . Use investigational drug product , within 30 day 7 . History clinically significant drug allergy sensitivities 8 . Females positive pregnancy test breast feed Screening plan breast feed within 30 day dose 9 . A baseline QTc interval ≥ 490 millisecond male ≥ 510 millisecond females 10 . Is unable refrain alcohol 11 . Has take prescription counter medication within 7 day prior treatment day , opinion Investigator , could expect confound PK metabolism study drug 12 . Has take follow herbal agent nutraceuticals within 7 day prior Screening : chapparal , comfrey , germander , gin bu huan , kava , pennyroyal , skullcap , St. John 's Wort , valerian 13 . Has poorly control malignant hypertension ( systolic blood pressure [ SBP ] &gt; 200 mm Hg and/or diastolic blood pressure [ DBP ] &gt; 120 mm Hg , 14 . Concurrent use uratelowering drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Chronic Kidney Disease Stage 5</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>pegloticase</keyword>
</DOC>